Welcome to our dedicated page for PHAS news (Ticker: PHAS), a resource for investors and traders seeking the latest updates and insights on PHAS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PHAS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PHAS's position in the market.
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS) has announced the discontinuation of its VANGARD clinical trial after evaluating interim data and feedback from the FDA regarding the treatment landscape for COVID-19. Although pemziviptadil was well tolerated with no safety concerns, the company concluded that the trial's sample size was insufficient to assess mortality risk adequately. PhaseBio plans to refocus on its ongoing Phase 2b VIP Trial for pulmonary arterial hypertension, with results expected later in 2021.
PhaseBio Pharmaceuticals (Nasdaq: PHAS) has expanded its pivotal Phase 3 REVERSE-IT trial for bentracimab, a novel therapy aimed at reversing the antiplatelet effects of the drug Brilinta, into Canada. This expansion includes the enrollment of the first patients outside the U.S. Bentracimab has shown promise in earlier trials for providing immediate and sustained reversal of ticagrelor's effects, addressing a significant clinical need amid rising cardiovascular issues. The REVERSE-IT trial targets approximately 200 patients globally, focusing on those requiring urgent reversal.
